Neoplasms

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Carcinoma

Neoplasm Metastasis

Carcinoma, Hepatocellular

Recurrence

Neoplastic Processes

Disease Attributes

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

All Drugs and Chemicals

Anti-Infective Agents

Immunomodulating Agents

Antiviral Agents

Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..

Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.

Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.

During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.

Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.

Huaier Granule

Xiaoping Chen, Professor

To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and metastasis of hepatocarcinoma after radical hepatectomy.

A Multicenter, Randomized, Paralleled control Clinical Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma after Radical Hepatectomy,to evaluate the efficacy and safety.

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy

A Multicenter, Randomized, Paralleled Control Clinical Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy

At week 94 after took medicine, assess incidence of recurrence and metastasis after hepatectomy.

Huazhong University of Science and Technology

Qidong Gaitianli Medicines Co., Ltd

Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..

Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule.

Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.

Huaier Granule Group

Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.

During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles.

Huaier Granule: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.

Bank-control Group

Total

Age, Categorical

Sex: Female, Male

China

Region of Enrollment

Number of tumor

Incidence of Recurrence and Metastasis After Hepatectomy

Postoperative Survival Period

Overall Study

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Antineoplastic Agents

Cetuximab

Cisplatin

Antineoplastic Agents, Immunological

400mg/m\^2 intravenous infusion one week before radiotherapy, then 250mg/m\^2 intravenous infusion weekly during radiotherapy

one week before and then weekly during radiotherapy

C225 (cetuximab)

Tai-xiang Lu, M.D.

Tong-yu Lin, M.D., PhD

This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy

Phase II Study of Cetuximab Combined With Intensity Modulated Radiotherapy (IMRT) and Concurrent Chemotherapy of Cisplatin in Nasopharyngeal Carcinoma

The response status (Complete Response + Partial Response) was evaluated according to RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Complete response was defined as disappearance of all target lesions, and Partial response was defined as at least a 30% reduction in the sum of the longest diameter of target lesions, taking as reference the baseline study.

Adverse events of this combined modality treatment were graded according to CTCAE (Common Terminology Criteria for Adverse Events) v3.0 criteria.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Sichuan Cancer Hospital and Research Institute

Fujian Cancer Hospital

Fudan University

Cancer Hospital of Guizhou Province

First Affiliated Hospital of Guangxi Medical University

Central South University

Sun Yat-sen University

Departments of Radiation Oncology

Age Continuous

Dr. Lu Tai-xiang

3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy

1,3,5 Year Loco-regional Control Rate, 1 Year Progression-free Survival and Metastasis-free Survival, 3 and 5 Year Overall Survival

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy	NCT01770431	Hepatic Carcino...	Huaier Granule	18 Years - 75 Years	Qidong Gaitianli Medicines Co., Ltd
Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy	NCT00700440	Nasopharyngeal ...	C225 (cetuximab...	18 Years - 69 Years	Sun Yat-sen University
Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy	NCT00700440	Nasopharyngeal ...	C225 (cetuximab...	18 Years - 69 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for safety.

Every month we try and update this database with for safety. cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for safety.

Every month we try and update this database with for safety. cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for safety. cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.